voxelotor
Pronunciation: /ˈvɒksəlɔːtɔr/
Oral medication that increases oxygen affinity of hemoglobin S to prevent sickling and improve anemia in sickle cell disease.
Full Definition
Voxelotor is an oral hemoglobin S polymerization inhibitor that works by increasing the affinity of hemoglobin S for oxygen, thereby preventing the formation of sickled red blood cells. The drug binds to the N-terminal valine of hemoglobin S, stabilizing the oxygenated state and reducing polymerization. Clinical trials have demonstrated improvements in hemoglobin levels and markers of hemolysis in patients with sickle cell disease. Voxelotor is approved for patients 12 years and older and represents a disease-modifying therapy that directly targets the underlying pathophysiology.
Usage
Usage note: Generic name preferred over brand name Oxbryta. Include dosing with food instructions.
In Context
- "The patient's hemoglobin level increased from 7.2 to 9.1 g/dL after starting voxelotor therapy." — Follow-up clinic note
- "Voxelotor should be taken with food to optimize absorption and reduce gastrointestinal side effects." — Medication counseling